A 72-year-old man with histologically confirmed prostate cancer is being evaluated for treatment options. His oncologist discusses various therapeutic modalities including surgery, radiation, and hormone therapy. All of the following statements regarding prostate cancer management are true EXCEPT:

Explanation

## Prostate Cancer Management Strategies ### Treatment Modalities by Stage and Risk **Key Point:** Prostate cancer management is individualized based on stage, grade, PSA level, patient age, comorbidities, and life expectancy. ### Localized Prostate Cancer Treatment Options | Modality | Indication | Role | |----------|-----------|------| | Radical prostatectomy | Localized disease, fit patient, life expectancy > 10 years | Gold standard for younger, healthy men | | External beam radiation (EBRT) | Localized/locally advanced disease | Effective; less invasive than surgery | | Brachytherapy | Low-to-intermediate risk, localized disease | Excellent outcomes for selected cases | | EBRT + Brachytherapy | Intermediate-to-high risk disease | Superior to EBRT alone in high-risk patients | | Active surveillance | Low-risk, early-stage disease | Avoids overtreatment; requires strict monitoring | | ADT | Metastatic disease, high-risk localized disease | First-line for metastatic HSPC | ### Analysis of Each Statement #### Statement 1: Radical Prostatectomy (TRUE) **High-Yield:** Radical prostatectomy is indeed the gold standard for localized prostate cancer in fit, younger patients with life expectancy > 10 years. It offers excellent oncologic control and allows for pathologic staging. #### Statement 2: ADT for Metastatic Disease (TRUE) **Clinical Pearl:** Androgen deprivation therapy (ADT) — either GnRH agonists/antagonists or bilateral orchiectomy — is the first-line treatment for metastatic hormone-sensitive prostate cancer (mHSPC). It induces apoptosis of androgen-dependent cancer cells and provides rapid PSA response and symptom relief. #### Statement 3: EBRT + Brachytherapy (FALSE — THE ANSWER) **Warning:** This is the trap. While EBRT + brachytherapy IS superior to EBRT alone in **high-risk and intermediate-risk** localized prostate cancer, it is **NOT superior in ALL cases**. In **low-risk** localized disease, EBRT alone or brachytherapy alone provides excellent outcomes, and the addition of brachytherapy increases toxicity without significant benefit. The statement overgeneralizes by saying "in all cases." **Key Point:** The combination of EBRT + brachytherapy is reserved for intermediate-to-high-risk disease. In low-risk disease, monotherapy (EBRT or brachytherapy alone) is preferred to minimize morbidity. #### Statement 4: Active Surveillance (TRUE) **High-Yield:** Active surveillance is an appropriate, evidence-based strategy for low-risk, early-stage prostate cancer. Criteria include Gleason ≤ 6, PSA < 10 ng/mL, and clinical stage T1–T2a. PSA doubling time > 3 years is a favorable prognostic sign within surveillance cohorts. This approach avoids overtreatment of indolent tumors while allowing intervention if progression occurs. ### Why Statement 3 is the Exception The statement claims EBRT + brachytherapy is superior "in all cases," which is false. Risk-adapted therapy is the principle: - **Low-risk:** EBRT alone or brachytherapy alone - **Intermediate/High-risk:** EBRT + brachytherapy ± ADT Adding brachytherapy to EBRT in low-risk disease increases treatment burden and toxicity without proven survival benefit.